Skip to main content
Signal8

IMPACT BIOMEDICAL INC. (IBO)

Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Impact BioMedical Inc. logo

Impact BioMedical Inc.

NYSE:IBOHealthcare
Pre-3.38%$3.43
Close$3.55-4.83%AH$3.55-3.38%since
Mkt Cap$30.33M
Float938K
O/S8.54M
Inst Own3.6%
SI2.8%
Dilution
Impact BioMedical Inc. logoNYSE:IBOPre$3.43-3.38%
FormDescription
DEFM14A
SEC Filing
8
8-K
5.03,9.01
3
4
Statement of Changes in Beneficial Ownership
425
Business Combination Communication
8-K
7.01,9.01
3
425
Business Combination Communication
8-K
7.01,9.01
6
10-Q
10-Q
Quarterly Report
144
Notice of Proposed Sale of Securities
S-8 POS
SEC Filing
S-8 POS
SEC Filing
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
10-K
Annual Report
8-K
1.01,9.01
4
Statement of Changes in Beneficial Ownership
DEF 14C
Definitive Information Statement
PRE 14C
SEC Filing
10-Q
Quarterly Report
8-K
5.07
8-K
8.01
DEF 14A
Definitive Proxy Statement
DEF 14C
Definitive Information Statement
PRE 14C
SEC Filing

1-25 of 144

…